The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Celgene; Roche
Consulting or Advisory Role - Celgene; Myelo Therapeutics GmbH
 
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Hexal; Nektar; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
 
Volker Moebus
No Relationships to Disclose
 
Stefanie Noeding
No Relationships to Disclose
 
Ekkehart Ladda
No Relationships to Disclose
 
Peter Klare
No Relationships to Disclose
 
Marcus Schmidt
Honoraria - Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer; Roche
Speakers' Bureau - Novartis; Pfizer; Roche
Research Funding - Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca; Celgene; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Pfizer (Inst); Roche Pharma AG (Inst)
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen; Celgene; Roche
 
Wolfgang Janni
Honoraria - Janssen Diagnostics
Research Funding - Janssen Diagnostics
 
Frederik Marmé
Honoraria - Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Celgene; Eisai; Novartis; Pfizer; Pharmamar-zeltia; Roche
 
Toralf Reimer
No Relationships to Disclose
 
Sabine Schmatloch
No Relationships to Disclose
 
Elmar Stickeler
Honoraria - Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Michael Untch
No Relationships to Disclose
 
Bruno Valentin Sinn
No Relationships to Disclose
 
Volkmar Müller
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Amgen; Celgene; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst)
 
Gunter Von Minckwitz
Stock and Other Ownership Interests - CARA GmbH
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Myriad Genetics (Inst); Pfizer (Inst); Roche (Inst); Vifor Pharma (Inst)
 
Jenny Furlanetto
No Relationships to Disclose
 
Nicole Burchardi
No Relationships to Disclose
 
Sibylle Loibl
Honoraria - Pfizer; Roche
Consulting or Advisory Role - Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Teva (Inst); Vifor Pharma (Inst)